Abby Hardy, Author at BioTuesdays

Developments

Albireo initiates Phase 3 Alagille syndrome trial

Albireo Pharma (NASDAQ:ALBO) launched a Phase 3 trial evaluating odevixibat for the treatment of Alagille syndrome, a rare genetic disorder that affects multiple parts of the body. Most Alagille patients present with...

December 17, 2020

Developments

Aldeyra initiates 3 Phase 2 trials of ADX-629

Aldeyra Therapeutics (NASDAQ:ALDX) launched three Phase 2 trials evaluating ADX-629 for the treatment of COVID-19, atopic asthma, and psoriasis. ADX-629 is an orally administered RASP inhibitor designed to modulate the...

December 17, 2020

Developments

vTv Therapeutics azeliragon fails Phase 2 AD and T2D trial

vTv Therapeutics’ (NASDAQ:VTVT) Phase 2 trial of azeliragon in patients with Alzheimer’s disease (AD) and Type 2 diabetes (T2D) failed to meet its primary endpoint. The trial enrolled 43 patients who were randomized to...

December 16, 2020

Developments

Durect gets FDA fast track designation for alcoholic hepatitis

Durect’s (NASDAQ:DRRX) DUR-928 received FDA fast track designation for the treatment of alcoholic hepatitis (AH), a life-threatening form of alcohol-associated liver disease. In August 2020, Durect reported results of...

December 16, 2020

Developments

Verastem initiates Phase 2 non-small lung cancer trial

Verastem (NASDAQ:VSTM) initiated a Phase 2 registration-directed trial evaluating VS-6766 for the treatment of KRAS-G12V-mutant non-small cell lung cancer (NSCLC). In the first part of the study, VS-6766, a RAF/MEK...

December 15, 2020

Developments

Kiniksa Pharma initiates dosing in Phase 2b prurigo nodularis trial

Kiniksa Pharmaceuticals (NASDAQ:KNSA) initiated dosing in its Phase 2b trial evaluating vixarelimab for the treatment of prurigo nodularis. Prurigo nodularis is a skin disease that causes hard, itchy nodules to form on...

December 15, 2020

Feature

Ripple Therapeutics lead candidate attracts strategic investment and licensing partner

Closely-held Ripple Therapeutics inked a transformative strategic investment and licensing deal for its lead product candidate, IBE-814 IVT, an intravitreal implant being developed for the treatment of diabetic macular...

December 15, 2020

Developments

Aerpio reports positive topline results from Phase 2 glaucoma trial

Aerpio Pharma (NASDAQ:ARPO) reported positive topline results from its Phase 2 trial evaluating razuprotafib for the treatment of elevated intraocular pressure (IOP). The study enrolled 194 patients with elevated IOP...

December 14, 2020

Developments

Prevail Therapeutics doses first patient in Phase 1/2 frontotemporal dementia trial

Prevail Therapeutics (NASDAQ:PRVL) dosed the first patient in its Phase 1/2 PROCLAIM trial evaluating PR006 for the treatment of frontotemporal dementia patients with GRN mutations. Frontotemporal dementia is the second...

December 11, 2020

Developments

Geron begins enrollment in Phase 3 refractory myelofibrosis trial

Geron (NASDAQ:GERN) reported that its Phase 3 IMpactMF clinical trial, which is evaluating imetelstat for the treatment of refractory myelofibrosis, is open for patient screening and enrollment. The trial is designed to...

December 11, 2020

Author - Abby Hardy

Albireo initiates Phase 3 Alagille syndrome trial

Aldeyra initiates 3 Phase 2 trials of ADX-629

vTv Therapeutics azeliragon fails Phase 2 AD and T2D trial

Durect gets FDA fast track designation for alcoholic hepatitis

Verastem initiates Phase 2 non-small lung cancer trial

Kiniksa Pharma initiates dosing in Phase 2b prurigo nodularis trial

Ripple Therapeutics lead candidate attracts strategic investment and licensing partner

Aerpio reports positive topline results from Phase 2 glaucoma trial

Prevail Therapeutics doses first patient in Phase 1/2 frontotemporal dementia trial

Geron begins enrollment in Phase 3 refractory myelofibrosis trial

General

More